5ARIs and PSA: Evidence

    May 2014 in “ Urologia Journal ”
    Giuseppe Morgia, Daniele Urzì, Giorgio Ivan Russo
    Studysummary This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.sagepub.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. The Effect of Finasteride in Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1992

    Related research 6

    1. Evaluation of the Therapeutic Effects of AGA Drugs by Measuring Finasteride, Dutasteride, and Dihydrotestosterone in Hair Clinica Chimica Acta · 2023
    2. What Do We Know About 5-Alpha Reductase Inhibitors? Surgical and Cosmetic Dermatology · 2018
    3. Dutasteride in Androgenetic Alopecia: An Update Current Clinical Pharmacology · 2017
    4. Dutasteride for Men with Androgenic Alopecia Unresponsive to Finasteride Journal of Investigative Dermatology · 2016
    5. Atypical Post-Finasteride Syndrome: A Pharmacological Riddle Indian Journal of Pharmacology · 2016
    6. The Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice The FASEB Journal · 2013